Modificazioni dei marcatori di rimodellamento osseo in pazienti trattati con neridronato per osteoporosi indotta da glucocorticoidi

Translated title of the contribution: Modifications of markers of bone resorption in patients affected by glucocorticoid induced osteoporosis (GIOP) treated with neridronate

Maurizio Benucci, Stefano Dolenti, Gianantonio Saviola, Mariangela Manfredi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Almost 30-50% of patients on long-term therapy with glucocorticoids (GC), especially those affected by rheumatic diseases, develop glucocorticoid induced osteoporosis (GIOP) and osteoporosis-related fractures. To assess the effects of neridronate versus placebo on markers of bone resorption in rheumatic patients affected by GIOP (as defined by a T Score reduction >2.5; mean BMD L2-L4), sixty-two female patients [age: 68.89±9.45 (mean±SD)] affected by different rheumatic diseases, like rheumatoid arthritis, polymyalgia rheumatica, Sjögren syndrome in treatment with a mean prednisone-equivalent daily dose of 6.44±2.4 mg/day, were enrolled in an open trial. The patients were divided in 2 groups: group A (26 patients) assuming daily calcium 1 g and vitamin D 800 UI and group B (36 patients) assuming daily calcium (1000mg) and vitamin D (800 UI) and neridronate (25 mg im /30 days). The patients were evaluated for serum and urinary bone markers, basely (TO) and after 6 months of therapy (T6). After 6 months of therapy (T6), bone markers were significantly reduced in group B in respect to group A: OHPr - 41.64% (p

Original languageItalian
Pages (from-to)24-27
Number of pages4
JournalRecenti Progressi in Medicina
Volume97
Issue number1
Publication statusPublished - Jan 2006

Fingerprint

Bone Resorption
Glucocorticoids
Osteoporosis
Rheumatic Diseases
Vitamin D
Polymyalgia Rheumatica
Calcium
Bone and Bones
Therapeutics
Prednisone
6-amino-1-hydroxyhexane-1,1-diphosphonate
Rheumatoid Arthritis
Placebos
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Modificazioni dei marcatori di rimodellamento osseo in pazienti trattati con neridronato per osteoporosi indotta da glucocorticoidi. / Benucci, Maurizio; Dolenti, Stefano; Saviola, Gianantonio; Manfredi, Mariangela.

In: Recenti Progressi in Medicina, Vol. 97, No. 1, 01.2006, p. 24-27.

Research output: Contribution to journalArticle

@article{eed11f9bca1d47f183386d51b82da4cf,
title = "Modificazioni dei marcatori di rimodellamento osseo in pazienti trattati con neridronato per osteoporosi indotta da glucocorticoidi",
abstract = "Almost 30-50{\%} of patients on long-term therapy with glucocorticoids (GC), especially those affected by rheumatic diseases, develop glucocorticoid induced osteoporosis (GIOP) and osteoporosis-related fractures. To assess the effects of neridronate versus placebo on markers of bone resorption in rheumatic patients affected by GIOP (as defined by a T Score reduction >2.5; mean BMD L2-L4), sixty-two female patients [age: 68.89±9.45 (mean±SD)] affected by different rheumatic diseases, like rheumatoid arthritis, polymyalgia rheumatica, Sj{\"o}gren syndrome in treatment with a mean prednisone-equivalent daily dose of 6.44±2.4 mg/day, were enrolled in an open trial. The patients were divided in 2 groups: group A (26 patients) assuming daily calcium 1 g and vitamin D 800 UI and group B (36 patients) assuming daily calcium (1000mg) and vitamin D (800 UI) and neridronate (25 mg im /30 days). The patients were evaluated for serum and urinary bone markers, basely (TO) and after 6 months of therapy (T6). After 6 months of therapy (T6), bone markers were significantly reduced in group B in respect to group A: OHPr - 41.64{\%} (p",
keywords = "Glucocorticoids induced osteoporosis, Neridronate, Rheumatic diseases",
author = "Maurizio Benucci and Stefano Dolenti and Gianantonio Saviola and Mariangela Manfredi",
year = "2006",
month = "1",
language = "Italian",
volume = "97",
pages = "24--27",
journal = "Recenti Progressi in Medicina",
issn = "0034-1193",
publisher = "Il Pensiero Scientifico Editore s.r.l.",
number = "1",

}

TY - JOUR

T1 - Modificazioni dei marcatori di rimodellamento osseo in pazienti trattati con neridronato per osteoporosi indotta da glucocorticoidi

AU - Benucci, Maurizio

AU - Dolenti, Stefano

AU - Saviola, Gianantonio

AU - Manfredi, Mariangela

PY - 2006/1

Y1 - 2006/1

N2 - Almost 30-50% of patients on long-term therapy with glucocorticoids (GC), especially those affected by rheumatic diseases, develop glucocorticoid induced osteoporosis (GIOP) and osteoporosis-related fractures. To assess the effects of neridronate versus placebo on markers of bone resorption in rheumatic patients affected by GIOP (as defined by a T Score reduction >2.5; mean BMD L2-L4), sixty-two female patients [age: 68.89±9.45 (mean±SD)] affected by different rheumatic diseases, like rheumatoid arthritis, polymyalgia rheumatica, Sjögren syndrome in treatment with a mean prednisone-equivalent daily dose of 6.44±2.4 mg/day, were enrolled in an open trial. The patients were divided in 2 groups: group A (26 patients) assuming daily calcium 1 g and vitamin D 800 UI and group B (36 patients) assuming daily calcium (1000mg) and vitamin D (800 UI) and neridronate (25 mg im /30 days). The patients were evaluated for serum and urinary bone markers, basely (TO) and after 6 months of therapy (T6). After 6 months of therapy (T6), bone markers were significantly reduced in group B in respect to group A: OHPr - 41.64% (p

AB - Almost 30-50% of patients on long-term therapy with glucocorticoids (GC), especially those affected by rheumatic diseases, develop glucocorticoid induced osteoporosis (GIOP) and osteoporosis-related fractures. To assess the effects of neridronate versus placebo on markers of bone resorption in rheumatic patients affected by GIOP (as defined by a T Score reduction >2.5; mean BMD L2-L4), sixty-two female patients [age: 68.89±9.45 (mean±SD)] affected by different rheumatic diseases, like rheumatoid arthritis, polymyalgia rheumatica, Sjögren syndrome in treatment with a mean prednisone-equivalent daily dose of 6.44±2.4 mg/day, were enrolled in an open trial. The patients were divided in 2 groups: group A (26 patients) assuming daily calcium 1 g and vitamin D 800 UI and group B (36 patients) assuming daily calcium (1000mg) and vitamin D (800 UI) and neridronate (25 mg im /30 days). The patients were evaluated for serum and urinary bone markers, basely (TO) and after 6 months of therapy (T6). After 6 months of therapy (T6), bone markers were significantly reduced in group B in respect to group A: OHPr - 41.64% (p

KW - Glucocorticoids induced osteoporosis

KW - Neridronate

KW - Rheumatic diseases

UR - http://www.scopus.com/inward/record.url?scp=33645319765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645319765&partnerID=8YFLogxK

M3 - Articolo

C2 - 16535926

AN - SCOPUS:33645319765

VL - 97

SP - 24

EP - 27

JO - Recenti Progressi in Medicina

JF - Recenti Progressi in Medicina

SN - 0034-1193

IS - 1

ER -